2-[1-(4-Chlorobenzoyl)-2-phenylindol-3-yl]acetic acid | 1278540-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[1-(4-Chlorobenzoyl)-2-phenylindol-3-yl]acetic acid
• CAS: 1278540-55-8
• 化学式: C₂₃H₁₆ClNO₃
• 分子量: 389.838
• InChiKey: CTOLGLQYKWARIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-苯基-1H-吲哚-3-羧酸 在 盐酸 、 10% Pd/C 、 potassium tert-butylate 、 水 、 氢气 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， -40.0~20.0 ℃ 、101.33 kPa 条件下， 反应 32.0h， 生成 2-[1-(4-Chlorobenzoyl)-2-phenylindol-3-yl]acetic acid
  参考文献：
  名称：

  Design and Synthesis of Indomethacin Analogues That Inhibit P-Glycoprotein and/or Multidrug Resistant Protein without Cox Inhibitory Activity

  摘要：

  We designed and synthesized conformationally restricted analogues and regioisomers of the nonsteroidal anti-inflammatory drug indomethacin. Evaluation of the inhibitory effects of these compounds on COX, P-glycoprotein, and multidrug resistance indicated that NSAIDS modulation of multidrug-resistant P-glycoprotein and multidrug-resistant protein-1 is not associated with COX-1 and COX-2 inhibitory activities.

  DOI：

  10.1021/jm301084z

文献信息

• Indomethacin Analogues that Enhance Doxorubicin Cytotoxicity in Multidrug Resistant Cells without Cox Inhibitory Activity
  作者：Mitsuhiro Arisawa、Yayoi Kasaya、Tohru Obata、Takuma Sasaki、Mika Ito、Hiroshi Abe、Yoshihiro Ito、Akihito Yamano、Satoshi Shuto

  DOI：10.1021/ml100292y

  日期：2011.5.12

  Conformationally restricted indomethacin analogues were designed and prepared from the corresponding 2-substituted indoles, which were synthesized by a one-pot isomerization/enamide-ene metathesis as the key reaction. Conformational analysis by calculations, NMR studies, and X-ray crystallography suggested that these analogues were conformationally restricted in the s-cis or the s-trans form due to the 2-substituent as expected. Their biological activities on cyclooxygenase-1 (COX-1) inhibition, cyclooxygenase-2 (COX-2) inhibition, and modulation of MRP-1-mediated multidrug resistance (MDR) are described. Some of these indomethacin analogues enhanced doxorubicin cytotoxicity, although they do not have any COX inhibitory activity, which suggests that the MDR-modulating effect of an NSAID can be unassociated with its COX-inhibitory activity. This may be an entry into the combination chemotherapy of doxorubicin with a MDR modulator.
• Design and Synthesis of Indomethacin Analogues That Inhibit P-Glycoprotein and/or Multidrug Resistant Protein without Cox Inhibitory Activity
  作者：Mitsuhiro Arisawa、Yayoi Kasaya、Tohru Obata、Takuma Sasaki、Tomonori Nakamura、Takuya Araki、Koujirou Yamamoto、Akito Sasaki、Akihito Yamano、Mika Ito、Hiroshi Abe、Yoshihiro Ito、Satoshi Shuto

  DOI：10.1021/jm301084z

  日期：2012.9.27

  We designed and synthesized conformationally restricted analogues and regioisomers of the nonsteroidal anti-inflammatory drug indomethacin. Evaluation of the inhibitory effects of these compounds on COX, P-glycoprotein, and multidrug resistance indicated that NSAIDS modulation of multidrug-resistant P-glycoprotein and multidrug-resistant protein-1 is not associated with COX-1 and COX-2 inhibitory activities.